Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03215706 · OUTCOME

Overall Survival (OS)

A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC · Source last updated 2025-12-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
From date of randomization to date of death (assessed up to October 2024, approximately 72 months)

What was measured

OS was defined as the time from randomization to the date of death from any cause. OS was censored on the last date a subject was known to be alive. Survival follow-up was to be conducted every 3 months after participants's off-treatment date.

Analysis population: All Randomized Participants, Global Population

Groups in this outcome

Treatment A

Nivolumab + Ipilimumab + Chemotherapy

Treatment B

Chemotherapy only

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment A361
Treatment B358

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment A15.80Not reported13.9319.71Not reported
Treatment B10.96Not reported9.4912.71Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Lower Limit
    0.63
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    0.87
    group Ids
    1. OG000
    2. OG001
    non Inferiority Comment
    Treatment A over Treatment B
    non Inferiority Type
    SUPERIORITY
    param Type
    Hazard Ratio (HR)
    param Value
    0.74
    statistical Method
    Stratified Cox proportional hazard model
Complete source fields
analyses
  1. ci Lower Limit
    0.63
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    0.87
    group Ids
    1. OG000
    2. OG001
    non Inferiority Comment
    Treatment A over Treatment B
    non Inferiority Type
    SUPERIORITY
    param Type
    Hazard Ratio (HR)
    param Value
    0.74
    statistical Method
    Stratified Cox proportional hazard model
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        13.93
        upper Limit
        19.71
        value
        15.80
      2. group Id
        OG001
        lower Limit
        9.49
        upper Limit
        12.71
        value
        10.96
denoms
  1. counts
    1. group Id
      OG000
      value
      361
    2. group Id
      OG001
      value
      358
    units
    Participants
description
OS was defined as the time from randomization to the date of death from any cause. OS was censored on the last date a subject was known to be alive. Survival follow-up was to be conducted every 3 months after participants's off-treatment date.
dispersion Type
95% Confidence Interval
groups
  1. description
    Nivolumab + Ipilimumab + Chemotherapy
    id
    OG000
    title
    Treatment A
  2. description
    Chemotherapy only
    id
    OG001
    title
    Treatment B
param Type
MEDIAN
population Description
All Randomized Participants, Global Population
reporting Status
POSTED
time Frame
From date of randomization to date of death (assessed up to October 2024, approximately 72 months)
title
Overall Survival (OS)
type
POST_HOC
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice